炎症与肿瘤的发生机制及脂氧素功能研究。

The mechanism of inflammation and tumor and the function of lipoxin.

同济大学附属杨浦医院病理科副主任（主持工作），病理科学科带头人，同济大学副教授，上海市医学会病理专科分会委员华中科技大学同济医学院病理学与病理生理学专业博士毕业。

Director of Department of Pathology, Yangpu Hospital, School of Medicine, Tongji University, Acatemic Leader of Pathology Department, Associate Professor of Tongji University, committee member of Pathology sub-committee of Shanghai Medical Association, graduated from Tongji Medical College, Huazhong University of Science & Technology, major in Pathology and Pathophysiology.

Cancer Letters、Journal of Translational Medicine、Journal of Leukocyte Biology、European Journal of Medical Research、Journal of Cosmetic Dermatology、Renal Failure等杂志审稿专家，主持国家自然科学基金1项，省部级课题5项，市厅级课题4项，院级课题3项。发表一作及通讯作者SCI论文13篇。

发表SCI论文：

1. Hao H, Xie F, Xu F, Wang Q, Wu Y, Zhang D. LipoxinA4 analog BML-111 protects podocytes cultured in high-glucose medium against oxidative injury via activating Nrf2 pathway. International Immunopharmacology, 2022, 111:109170.

2. Zhang J, Zhou X, Hao H* (通讯作者). Macrophage phenotype-switching in cancer. European Journal of Pharmacology, 2022, 931:175229.

3. Xu F, Zhang J, Zhou X, Hao H* (通讯作者). Lipoxin A4 and its analog attenuate high fat diet-induced atherosclerosis via Keap1/Nrf2 pathway. Experimental Cell Research, 2022, 412:113025.

4. Lin L, Wang Q, Xu F, Luo X, Xu J, Yan L, Li Q, Hao H* (通讯作者). BML-111, the lipoxin A4 agonist, modulates VEGF or CoCl2-induced migration, angiogenesis and permeability in tumor-derived endothelial cells. Immunology Letters, 2021,230: 27-35.

5. Lin L, Luo XL, Wang L, Xu F, He YQ, Wang QY, Yuan CL, Xu J, Yan LP, Hao H* (通讯作者). BML-111 inhibits EMT, migration and metastasis of TAMs-stimulated triplenegative breast cancer cells via ILK pathway. International Immunopharmacology, 2020, 85:106625.

6. Zhang T, Hao H (并列第一作者), Zhou ZQ, Zeng T, Zhang JM, Zhou XY. Lipoxin A4 inhibited the activation of Hepatic Stellate Cells -T6 cells by modulating profibrotic cytokines and NF-κB signaling pathway. Prostaglandins & Other Lipid Mediators, 2020, 146:106380.

7. Zhang T, Hao H (并列第一作者), Zhou X. The Role of Lipoxin in Regulating Tumor Immune Microenvironments. Prostaglandins & Other Lipid Mediators, 2020,144:106341.

8. Li QF, Hao H (并列第一作者), Tu WS, Guo N, Zhou XY. Maresins: anti-inflammatory pro-resolving mediators with therapeutic potential. European Review for Medical and Pharmacological Sciences, 2020, 24: 7442-7453.

9. Chen QF, Hao H (并列第一作者), Kuang XD, Hu QD, Huang YH, Zhou XY. BML-111, a lipoxin receptor agonist, protects against acute injury via regulating the renin angiotensin-aldosterone system. Prostaglandins & Other Lipid Mediators, 2019,140:9-17.

10. Xu F, Zhou X, Hao J, Dai H, Zhang J, He Y, Hao H*（通讯作者）. Lipoxin A4 and its analog suppress hepatocarcinoma cell epithelial-mesenchymal transition, migration and metastasis via regulating integrin-linked kinase axis. Prostaglandins & Other Lipid Mediators, 2018,137:9-19.

11. Hao H*（通讯作者）, Xu F, Hao J, He YQ, Zhou XY, Dai H, Wu LQ, Liu FR. Lipoxin A4 suppresses lipopolysaccharide-induced Hela cell proliferation, migration via NF-κB pathway. Inflammation, 2015,38(1):400-8.

12. Hao H, Liu M, Wu P, Cai L, Tang K, Yi P, Li Y, Chen Y, Ye D. Lipoxin A4 and its analog suppress hepatocellular carcinoma via remodeling tumor microenvironment. Cancer Letters, 2011,309(1):85-94.

13. Chen Y, Hao H（并列第一作者）, He S, Cai L, Li Y, Hu S, Ye D, Hoidal J, Wu P, Chen X. Lipoxin A4 and its analogue suppress the tumor growth of transplanted H22 in mice: the role of antiangiogenesis. Molecular Cancer Therapeutics, 2010,9(8):2164-74.